5 March 2013
Dechra Pharmaceuticals PLC
(the "Company")
Director / PDMR Shareholding
The Company announces that the following Directors/PDMRs were today granted nil cost options over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the "Plan"):
Name of individual |
Director/PDMR |
Type of award |
Number of shares subject to award |
Ian Page |
Director |
Option |
94,420 |
Tony Griffin |
Director |
Option |
34,401 |
Ed Torr |
Director |
Option |
32,838 |
Zoe Goulding |
PDMR |
Option |
17,167 |
The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share ("EPS") and its Total Shareholder Return ("TSR") relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed ("ROCE") performance measure. If the ROCE performance condition is not met, then the LTIP options will lapse in full.
For further information, please contact:
Zoe Goulding, Company Secretary
Telephone number: 01782 771100
About Dechra
Dechra is an international veterinary pharmaceutical business. Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.